News Sentiment

NRXP sentiment intelligence

NRX Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.19 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+8.3% over one week, +9.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Is NRx Pharmaceuticals, Inc. (NRXP) Stock Positioned for Growth Through Depression and PTSD Treatment Innovation?

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction 8.3% Price confirming higher
Trend fit Trend active 9.1% over four weeks
Fair value 46.9% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 35
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 19
TradingView 11
Stock Titan 6
MT Newswires 3
simplywall.st 3
GlobeNewswire 2
Investing News Network 2
TradingKey 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 15
Deals and strategy 4
Regulatory and legal 4
Guidance 2
Analyst action 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
TradingView Direct company coverage

Equity in earnings of NRX Pharmaceuticals, Inc. – DUS:B1Q

This article provides financial information for NRX Pharmaceuticals, Inc. (DUS:B1Q) as listed on the Dusseldorf Stock Exchange. It specifically highlights the "Equity in earnings" for the company. The content appears to be a stub or a section from a larger financial data platform

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 06:12
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP

The article focuses on the enterprise value to revenue forward metric for NRX Pharmaceuticals, Inc. (NASDAQ: NRXP). It appears to be a financial data snippet from TradingView, indicating no current trades and providing an overview of where to find financial and market information

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 11:09
Source
TradingView
Barchart.com Direct company coverage

First Patients Treated via FDA-Cleared Transcranial Magnetic Stimulation, Plus FDA Grant on D-Cycloserine-Based Drug for Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

NRx Pharmaceuticals, Inc. (NRXP) announced that its subsidiary, HOPE Therapeutics, has begun treating patients with the FDA-cleared Zeta TMS Navigation System for depression. Additionally, the FDA granted an Intermediate Population Expanded Access Protocol for NRX-101 (D-cycloser

Tone
Positive 70/100
Event
Market update
Published
30 Jun 2026 04:40
Source
Barchart.com
www.marketscreener.com Direct company coverage

NRx Pharmaceuticals, Inc.(NasdaqCM:NRXP) dropped from Russell 3000E Growth Benchmark

NRx Pharmaceuticals, Inc. (NasdaqCM: NRXP) has been removed from the Russell 3000E Growth Benchmark. The clinical-stage biopharmaceutical company focuses on developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD. The ar

Tone
Negative 30/100
Event
Market update
Published
29 Jun 2026 05:41
Source
www.marketscreener.com
marketscreener.com Direct company coverage

NRx Pharmaceuticals, Inc.(NasdaqCM:NRXP) dropped from Russell Microcap Growth Benchmark Index

NRx Pharmaceuticals, Inc. (NasdaqCM:NRXP) has been removed from the Russell Microcap Growth Benchmark Index. This follows a previous announcement on June 29th that the company was also dropped from the Russell 3000E Growth Benchmark. NRx Pharmaceuticals is a clinical-stage biopha

Tone
Negative 28/100
Event
Market update
Published
29 Jun 2026 03:39
Source
marketscreener.com
TradingView Direct company coverage

Enterprise value to revenue forward of NRX Pharmaceuticals, Inc. – DUS:B1Q

The article focuses on the enterprise value to revenue forward metric for NRX Pharmaceuticals, Inc. (DUS:B1Q), traded on the Dusseldorf Stock Exchange. It highlights financial data and market information related to the company's valuation. The content appears to be a stub or a se

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 16:10
Source
TradingView
Market source Direct company coverage

Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition

Kadima Neuropsychiatry Institute and its founder, Dr. David Feifel, have filed a lawsuit against NRx Pharmaceuticals (NASDAQ: NRXP) and its subsidiaries, alleging breach of contract and misrepresentation regarding an acquisition agreement. The suit claims NRx warranted it had suf

Tone
Negative 14/100
Event
Deals and strategy
Published
28 Jun 2026 05:09
Source
Market source
TradingView Direct company coverage

Price to book forward of NRX Pharmaceuticals, Inc. – DUS:B1Q

The article displays the "Price to book forward" for NRX Pharmaceuticals, Inc. (DUS:B1Q) on the Dusseldorf Stock Exchange according to TradingView. It indicates that the market is currently closed with no trades. The core content is limited to this financial metric and general ma

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 00:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of NRX Pharmaceuticals, Inc. – NASDAQ:NRXP

This article provides a brief snapshot of the "Price to sales forward" metric for NRX Pharmaceuticals, Inc. (NASDAQ: NRXP) as listed on TradingView. It indicates that no specific value or change information is currently displayed, suggesting the data may be unavailable or pending

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 00:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of NRX Pharmaceuticals, Inc. – DUS:B1Q

This article provides financial information for NRX Pharmaceuticals, Inc. (B1Q) on the Dusseldorf Stock Exchange. It specifically highlights the "Price to sales forward" metric for the company. The content appears to be a stub or a data point from a financial platform, indicating

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 23:39
Source
TradingView
Market source Direct company coverage

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, has started treating patients using Zeta Surgical's FDA-cleared Zeta TMS Navigation System at its clinics in Florida. This system employs AI-powered, sub-millimetric image guidance for Transcranial Magnetic Stimulation (TMS) pro

Tone
Positive 76/100
Event
Guidance
Published
27 Jun 2026 19:10
Source
Market source
Market source Direct company coverage

NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression

NRx Pharmaceuticals announced that the FDA has granted an Intermediate Population Expanded Access Protocol for NRX-101, a D-cycloserine-based drug, to augment Transcranial Magnetic Stimulation (TMS) in patients with treatment-resistant depression. This protocol allows access to N

Tone
Positive 90/100
Event
Market update
Published
26 Jun 2026 16:39
Source
Market source
The Globe and Mail Direct company coverage

H.C. Wainwright Keeps Their Buy Rating on NRX Pharmaceuticals (NRXP)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on NRX Pharmaceuticals (NRXP) with a $45.00 price target, highlighting his strong track record in the Healthcare sector. The analyst consensus for NRX Pharmaceuticals remains a Strong Buy with an average price targe

Tone
Positive 72/100
Event
Analyst action
Published
26 Jun 2026 12:49
Source
The Globe and Mail
TradingView Direct company coverage

NRX Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:NRXP)

This article provides an overview of NRX Pharmaceuticals, Inc. (NASDAQ: NRXP) stock performance, financial actuals, and analyst estimates. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports, along with an

Tone
Negative 32/100
Event
Earnings
Published
26 Jun 2026 04:39
Source
TradingView
GlobeNewswire Direct company coverage

NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute

NRx Pharmaceuticals (NRXP) issued a statement addressing "unfounded allegations" made by Kadima Neuropsychiatry Institute concerning the non-acquisition of Kadima by HOPE Therapeutics, an NRx subsidiary. NRx stated that it has compelled arbitration due to Kadima's failure to meet

Tone
Neutral 50/100
Event
Deals and strategy
Published
25 Jun 2026 20:09
Source
GlobeNewswire
Investing News Network Direct company coverage

NRx Pharmaceuticals Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has begun treating patients using Zeta Surgical's FDA-cleared Zeta TMS Navigation System at its clinics in West Palm Beach and Sarasota, Florida. This marks the transition from research deployment to active patient care, inc

Tone
Positive 75/100
Event
Market update
Published
25 Jun 2026 14:09
Source
Investing News Network
Stock Titan Direct company coverage

HOPE starts first FDA-cleared TMS treatments in Florida clinics

NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, has begun treating patients with Zeta Surgical's FDA-cleared Zeta TMS Navigation System in West Palm Beach and Sarasota, Florida. This system provides AI-guided, sub-millimetric image guidance for Transcranial Magnetic Stimulati

Tone
Positive 77/100
Event
Guidance
Published
25 Jun 2026 10:41
Source
Stock Titan
Investing.com Direct company coverage

Kadima sues NRx Pharmaceuticals over failed acquisition deal

Kadima Neuropsychiatry Institute has filed a lawsuit against NRx Pharmaceuticals and its subsidiaries, alleging breach of contract and misrepresentation regarding a failed acquisition deal. Kadima claims NRx announced the acquisition and saw a significant stock surge, but then in

Tone
Negative 13/100
Event
Deals and strategy
Published
24 Jun 2026 18:39
Source
Investing.com
TradingView Direct company coverage

EBIT per share of NRX Pharmaceuticals, Inc. – DUS:B1Q

The article provides the EBIT (Earnings Before Interest and Taxes) per share for NRX Pharmaceuticals, Inc., traded on the Dusseldorf Stock Exchange under the symbol B1Q. It indicates that the market is closed with no recent trades. The content is presented as a financial data poi

Tone
Neutral 50/100
Event
Earnings
Published
24 Jun 2026 13:39
Source
TradingView
TradingView Direct company coverage

Cash per share of NRX Pharmaceuticals, Inc. – DUS:B1Q

The article focuses on the "Cash per share" financial metric for NRX Pharmaceuticals, Inc. (DUS:B1Q) listed on the Dusseldorf Stock Exchange. It appears to be a financial data page from TradingView, indicating the company's financial overview, specifically its cash per share valu

Tone
Neutral 50/100
Event
Balance sheet
Published
24 Jun 2026 13:10
Source
TradingView
TradingView Direct company coverage

Tangible book value per share of NRX Pharmaceuticals, Inc. – DUS:B1Q

This article provides financial data for NRX Pharmaceuticals, Inc. (DUS:B1Q) from TradingView, specifically focusing on its tangible book value per share. The content indicates the market status as closed with no recent trades for the stock on the Dusseldorf Stock Exchange. It hi

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 22:12
Source
TradingView
grafa.com Direct company coverage

NRx Pharmaceuticals gets FDA approval for NRX-101 protocol

NRx Pharmaceuticals (NASDAQ:NRXP) has received FDA authorization for an expanded access program for its depression treatment drug candidate, NRX-101. This compassionate care decision allows the medication to be obtained by physicians with patients only covering shipping and data

Tone
Positive 71/100
Event
Regulatory and legal
Published
22 Jun 2026 13:46
Source
grafa.com
GlobeNewswire Direct company coverage

NRx Pharmaceuticals Announces FDA Grant of Expanded Access

NRx Pharmaceuticals announced that the FDA has granted an Intermediate Population Expanded Access Protocol for NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. This protocol allows the investigational drug to be used in conjunction with Transcranial Magnet

Tone
Positive 94/100
Event
Regulatory and legal
Published
22 Jun 2026 11:00
Source
GlobeNewswire
Stock Titan Direct company coverage

FDA lets NRx offer NRX-101 with TMS for severe depression

NRx Pharmaceuticals announced that the FDA has authorized an Intermediate Population Expanded Access Protocol for NRX-101 to be used with accelerated Transcranial Magnetic Stimulation (TMS) for Treatment-Resistant Depression. This protocol allows eligible patients to access the i

Tone
Positive 71/100
Event
Market update
Published
22 Jun 2026 11:00
Source
Stock Titan